Injection of nicardinpine hydrochloride and process for the production thereof
An injectable composition of nicardipine hydrochloride comprising an aqueous nicardipine hydrochloride solution containing 2-7 w/v % of polyhydric alcohol. This injectable composition can maintain its desired concentration and can be stably stored for a long period of time.
Latest Yamanouchi Pharmaceutical Co., Ltd. Patents:
This invention relates to an injectable composition of nicardipine hydrochloride having a cerebral vascular dilating activity, a coronary dilator activity, and an anti-hypertension activity. Also, the invention relates to a process of producing the injectable composition. More particularly, the invention relates to an injectable composition containing nicardipine hydrochloride and 2 to 7 W/V% of a polyhydric and a process of producing thereof.
BACKGROUND OF THE INVENTIONHitherto, oral administering formulations containing nicardipine hydrochloride have been developed but an injectable composition containing nicardipine hydrochloride has not yet been developed. This is because in the case of using the compound as an injectable composition, the compound shows a reduction in solubility according to the kind of isotonizing agent used and thus an injectable composition having a desired concentration cannot be obtained or the stability of an injectable composition if obtained is insufficient.
The inventors have investigated the possibility of obtaining a desired concentration of nicardipine hydrochloride and the stability of an injectable composition thereof by adding various additives for overcoming the above-described difficulties. As the result of the investigation, it has been found that when sodium chloride which is usually used as an isotonizing agent for injections is added, a desired concentration of nicardipine hydrochloride is not obtained and the injectable composition is insufficient in stability.
As the result of further investigations, it has been discovered that when nicardipine chloride is dissolved in water together with 2 to 7 W/V% of a polyhydric alcohol, a stable aqueous solution of nicardipine hydrochloride is unexpectedly obtained and based on the discovery, the invention has been attained.
SUMMARY OF THE INVENTIONThus, according to an embodiment of this invention, there is provided an injectable composition of nicardipine hydrochloride containing 2 to 7 W/V% of a polyhydric alcohol.
According to another embodiment of this invention, there is provided a process of producing an injectable composition of nicardipine hydrochloride which comprises dissolving nicardipine hydrochloride and a polyhydric alcohol in an amount of 2 to 7 W/V% of the total amount to water and adjusting the pH of the solution to 2.5 to 5.
The effect of this invention is greatly increased when the pH of the aqueous solution of nicardipine hydrochloride is adjusted to 2.5 to 5 as described above.
DESCRIPTION OF THE PREFERRED EMBODIMENTAccordingly, the invention will be explained in detail.
As the polyhydric alcohol for use in this invention, there are sorbitol, mannitol, xylitol, propylene glycol, glycerol, inositol, etc. They may be used individually or as a mixture of them. The amount of the polyhydric alcohol is about 2 to 7 W/V%, preferably about 5 W/V% based on the whole amount of the injectable composition. In addition, a certain polyhydric alcohol may show the insufficient isotonization by the use of about 2 W/V% and in such a case, the isotonization of the injectable composition may be controlled by using other isotonizing agent.
Also, if the pH of the injectable composition is lower than 2, the stability of nicardipine hydrochloride is reduced, while if the pH is higher than 6, the solubility of nicardipine hydrochloride is reduced.
There is no particular restriction about the concentration of nicardipine hydrochloride in this invention but is, as a matter of course, dependent upon the amount of the polyhydric alcohol and the pH thereof. By selecting a proper condition, a solubility of about 0.6 W/V% can be obtained.
The injectable composition of this invention is prepared by dissolving predetermined amounts of nicardipine hydrochloride and a polyhydric alcohol in water at 50 to 60.degree. C., adjusting the pH to about 2.5 to 5, preferably about 3.5, and then adjusting the volume of the solution to a predetermined volume by the addition of water. The pH of the solution can be controlled by a mineral acid such as hydrochloric acid and, as the case may be, by a base such as sodium hydroxide, sodium hydrogencarbonate, etc.
The injectable composition of nicardipine hydrochloride thus obtained can maintain its desired concentration (higher than 0.1 W/V%) and can be stored for a long period of time without being accompanied by the change in quality or stability. In addition, it is preferred to use light-resistant ampoules for the injectable composition.
The test relating to the stability of nicardipine hydrochloride and the result thereof are shown below.
A. Effect of polyhydric alcohol
(a) The case of storing at 60.degree. C.
(i) Sample:
The injectable composition of Example 1: Sorbitol (5 W/V%)
The injectable composition of Example 2: Mannitol (5 W/V%)
The injectable composition of Example 3: Xylitol (5 W/V%)
The injectable composition of Example 4: Propylene glycol (5 W/V%)
Control: An aqueous solution of nicardipine hydrochloride (0.1 W/V%, pH 3.5) containing no polyhydric alcohol.
(ii) Storage condition for sample: Each sample was stored in a bath maintained at 60.degree. C. and sampled at each definite period.
Quantitative determination: The quantitative determination was performed by a high performance chromatography (HPLC).
Condition of HPLC:
Column: Nucleosil C.sub.18 (150.times.4 mm)
Column temperature: 40.degree. C.
Eluent: Methanol-0.01M potassium hydrogen-phosphate solution (18:7)
Detection: Ultraviolet absorption detector Wave length 254 n.m.
(iv) Result: The remaining percentage of nicardipine hydrochloride in each sampled solution is shown in the following table.
______________________________________
Storage period (week)
Sample 0 4 8 12
______________________________________
Example 1 100 96.09 89.57
69.67
Example 2 100 93.08 88.26
71.63
Example 3 100 95.04 85.60
69.24
Example 4 100 97.20 88.03
74.39
Control 100 93.47 77.94
49.13
______________________________________
(b) The case of storing at 100.degree. C.
(i) Sample:
The injectable composition of Example 7: Sorbitol (2 W/V%)
The injectable composition of Example 8: Sorbitol (4 W/V%)
The injectable composition of Example 9: Mannitol (2 W/V%)
The injectable comopsition of Example 10: Mannitol (4 W/V%)
The injectable composition of Example 11: Xylitol (2 W/V%)
The injectable composition of Example 12: Xylitol (4 W/V%)
The injectable composition of Example 13: Propylene glycol (2 W/V%)
The injectable composition of Example 14: Propylene glycol (4 W/V%)
Control: Same as the case (a)
(ii) Storage condition of sample: Each sample was stored in a chamber at 100.degree. C. and sampled at each definite period.
(iii) Quantitative determination: Same as the case (a).
(iv) Result: The remaining percentage of nicardipine hydrochloride in each sampled solution is shown in the following table.
______________________________________
Storage day
Sample 1 3 7
______________________________________
Example 7 93.18 75.77 47.45
Example 8 92.98 79.62 49.66
Example 9 90.35 74.35 47.87
Example 10 92.43 78.27 50.03
Example 11 91.76 75.60 48.06
Example 12 94.26 78.43 50.28
Example 13 97.06 79.87 44.58
Example 14 92.39 78.02 45.77
Control 88.69 58.26 20.48
______________________________________
B. Influence of pH
(i) Sample:
The injectable composition of the Comparison example: pH 2.0
The injectable composition of Example 15: pH 3.0
The injectable composition of Example 16: pH 4.0
The injectable composition of Example 17: pH 5.0
(ii) Test condition of sample:
Each sample was stored in a chamber maintained at 100.degree. C. and sampled at each definite time.
(iii) Quantitative determination: Same as the case (a).
(iv) Result: The remaining percentage of nicardipine, hydrochloride in each sampled solution is shown in the following table.
______________________________________
Storage time (hr.)
Sample 0 2.5 5 10
______________________________________
Comparison 100 92.02 88.10
85.53
example (2.0)
Example 15 (3.0)
100 98.87 98.74
95.14
Example 16 (4.0)
100 99.18 99.68
99.73
Example 17 (5.0)
100 98.36 97.23
95.40
______________________________________
The following examples are intended to illustrate this invention but not to limit it in any way.
EXAMPLE 1About 2 liters of distilled water was heated to 50.degree. to 60.degree. C. and 2.5 g of nicardipine hydrochloride and 125 g of sorbitol were dissolved therein with stirring. After cooling the solution (pH about 4.5) thus obtained to room temperature, the pH thereof was adjusted to 3.5 using 0.1 N hydrochloric acid. Then, when the whole volume thereof was adjusted to 2.5 liters by the addition of distilled water and after filtering the solution, 5 ml each of the solution was filled in each light-resistant brown ampuol
EXAMPLE 2By following the same procedure as Example 1 using the same amount of mannitol in place of sorbitol, an injectable composition was obtained.
EXAMPLE 3By the following the same procedure as Example 1 using the same amount of xylitol in place of sorbitol, an injectable composition was obtained.
EXAMPLE 4By following the same procedure as Example 1 using the same amount of propylene glycol in place of sorbitol, an injectable composition was obtained.
EXAMPLE 5By the following the same procedure as Example 1 using the same amount of glycerol in place of sorbitol, an injectable composition was obtained.
EXAMPLE 6By following the same procedure as Example 1 using the same amount of inositol in place of sorbitol, an injectable composition was obtained.
EXAMPLE 7By following the same procedure as Example 1 using 50 g of sorbitol, an injectable composition was obtained.
EXAMPLE 8By following the same procedure as Example 1 using 100 g of sorbitol, an injectable composition was obtained.
EXAMPLE 9By following the same procedure as Example 2 using 50 g of mannitol, an injectable composition was obtained.
EXAMPLE 10By following the same procedure as Example 2 using 100 g of mannitol, an injectable composition was obtained.
EXAMPLE 11By following the same procedure as Example 3 using 50 g of xylitol, an injectable composition was obtained.
EXAMPLE 12By following the same procedure as Example 3 using 100 g of xylitol, an injectable composition was obtained.
EXAMPLE 13By following the same procedure as Example 4 using 50 g of propylene glycol, an injectable composition was obtained.
EXAMPLE 14By following the same procedure as Example 4 using 100 g of propylene glycol, an injectable composition was obtained.
EXAMPLE 15About 2 liters of distilled water was heated to 50.degree. to 60.degree. C. and 1.0 g of nicardipine hydrochloride and 125 g of sorbitol were dissolved therein with stirring. After cooling the solution (pH about 5.0) to room temperature, the pH of the solution was adjusted to 3.0 using 0.1 N hydrochloric acid. Then, the whole volume of the solution was adjusted to 2.5 liters by the addition of distilled water and after filtering the solution, 5 ml each of the solution was filled in each light-resistant brown ampuol.
EXAMPLE 16By following the same procedure as Example 15 while adjusting the pH of the solution to 4.0, an injectable composition was obtained.
EXAMPLE 17By following the same procedure as Example 15 while adjusting the pH of the solution to 5.0 using 0.1N sodium hydroxide in place of 0.1N hydrochloric acid, an injectable composition was obtained.
EXAMPLE 18By following the same procedure as Example 1 using 62.5 g of sorbitol and 62.5 g of mannitol in place of 125 g of sorbitol, an injectable composition was obtained.
COMPARISON EXAMPLEBy following the same procedure as Example 15 while adjusting the pH of the solution to 2.0, an injectable composition was obtained.
Claims
1. A stable, injectable composition of nicardipine hydrochloride.[.in ampoule form.]. comprising an aqueous nicardipine hydrochloride solution containing 0.04 to 0.6 W/V% nicardipine hydrochloride and 2 to 7 W/V% of a polyhydric alcohol and wherein the pH of said solution is from 2.5 to 5, and the percentage of nicardipine hydrochloride remaining in said solution after a 12 week storage period at 60.degree. C. is between 69.24 percent and 74.39 percent.
2. The stable injectable composition as claimed in claim 1, wherein the polyhydric alcohol is selected from the group consisting of sorbitol, mannitol, xylitol, propylene glycol, glycerol, and inositol..[.3. A process of producing a stable nicardipine hydrochloride injectable composition of claim 8, which process comprises dissolving nicardipine hydrochloride and a polyhydric alcohol in an amount of 2 to 7 W/V% of the whole amount of the injection in water and adjusting the pH of the solution to 2.5 to 5..]..[.4. The process as claimed in claim 3, wherein the polyhydric alcohol is selected from the group consisting of sorbitol,
mannitol, xylitol, propylene glycol, glycerol and inositol..]. 5. The stable injectable composition of claim 1 wherein the aqueous nicardipine
solution contains 0.1 to 0.6 W/V% nicardipine hydrochloride. 6. A process of producing a stable nicardipine hydrochloride injectable composition of claim 5, which process comprises dissolving nicardipine hydrochloride and a polyhydric alcohol in an amount of 2 to 7 W/V% of the whole amount of the injectable composition in water and adjusting the pH of the solution
to 2.5 to 5. 7. The process as claimed in claim 6 wherein the polyhydric alcohol is selected from the group consisting of sorbitol, mannitol, xylitol, propylene glycol, glycerol, and inositol.
| 4582840 | April 15, 1986 | Garthoff et al. |
| 1142937 | March 1983 | CAX |
- Odani et al, C.A. vol. 92 (1980) 92:104,384u.
Type: Grant
Filed: Nov 14, 1991
Date of Patent: May 24, 1994
Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Tokyo)
Inventors: Katayasu Ogawa (Saitama), Go Ohtani (Tokyo), Shoji Yokota (Tokyo), Masayoshi Aruga (Saitama)
Primary Examiner: Allen J. Robinson
Law Firm: Burgess, Ryan & White
Application Number: 7/791,358
International Classification: A61K 3144;
